董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Julie Klapstein | 女 | Director | 70 | 21.36万美元 | 2.29 | 2025-06-09 |
| Jonathan Root | 男 | Director | 66 | 21.92万美元 | 471.80 | 2025-06-09 |
| Sachin Jain | 男 | Director | 44 | 21.14万美元 | 2.62 | 2025-06-09 |
| Anne Beal | 女 | Director | 62 | 未披露 | 未持股 | 2025-06-09 |
| Sean Duffy | 男 | Chief Executive Officer, Co-Founder, and Director | 41 | 471.82万美元 | 201.38 | 2025-06-09 |
| Adam Stavisky | 男 | Director | 58 | 21.57万美元 | 2.29 | 2025-06-09 |
| Anne Beal | 女 | Director | 62 | 21.20万美元 | 未持股 | 2025-06-09 |
| Jeryl Hilleman | 女 | Chairperson and Lead Director | 67 | 27.73万美元 | 20.89 | 2025-06-09 |
| Trevor Fetter | 男 | Director | 65 | 22.53万美元 | 23.17 | 2025-06-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean Duffy | 男 | Chief Executive Officer, Co-Founder, and Director | 41 | 471.82万美元 | 201.38 | 2025-06-09 |
| Steve Cook | 男 | Chief Financial Officer | 39 | 213.77万美元 | 34.45 | 2025-06-09 |
| Wei Li Shao | 男 | President | 54 | 316.39万美元 | 57.91 | 2025-06-09 |
董事简历
中英对照 | 中文 | 英文- Julie Klapstein
-
Julie Klapstein预计将在本次发行完成前加入我们的董事会。Klapstein女士是Availity，LLC的创始首席执行官，该公司是一家优化梦百合利益相关者之间关键业务和临床信息自动传递的健康信息网络。Klapstein女士从2001年到2011年担任Availity&8217；的首席执行官兼董事会成员。她于2017年2月至2017年6月担任私营公司America，Inc.医疗报销的临时首席执行官。Klapstein女士目前任职于Amedisys的董事会，在那里她任职于治理和质量委员会，在那里她担任薪酬委员会主席，以及NextGen梦百合的董事会，在那里她担任薪酬委员会主席。她目前也任职于两家私人公司的董事会。Klapstein之前从2012年1月到2014年9月担任Annie&8217；s Homedrown/Annies，Inc.两家上市公司董事，2011年4月到2014年11月担任Standard Register Inc.治理、薪酬和审计委员会成员。她也一直担任多个私人公司的董事。Klapstein女士在俄勒冈州波特兰的波特兰州立大学（Portland State University）获得学士学位。
Julie Klapstein,has served as a member of board of directors since June 2024. Ms. Klapstein founded and served as the Chief Executive Officer of Availity, LLC, a healthcare information technology company, from May 2001 to March 2012. She also previously served as interim Chief Executive Officer of Medical Reimbursements of America, Inc., a provider of specialty reimbursement services, from February 2017 to June 2017. Ms. Klapstein has served on the boards of directors of Amedisys, Inc., a publicly held home healthcare provider, since April 2016, Claritev Corporation (f/k/a MultiPlan Corporation), a publicly held provider of business analytics and health cost management solutions, since November 2020, HealthCare Information Management, Inc., a robotic process automation company, since May 2024, Aptarro, Inc. (f/k/a Alpha II, LLC), a provider of revenue cycle management solutions for healthcare providers, since June 2024, and UnisLink Inc., a medical billing system vendor for healthcare providers, since July 2024, and also currently serves as an advisor to venture capital and private equity firms such as Andreessen Horowitz, GrowthCurve Capital, and Riverside Partners. She previously served on the boards of directors of numerous publicly held companies, including NextGen Healthcare, Inc., a healthcare technology company acquired by Thoma Bravo, from August 2017 to November 2023, and Oak Street Health, Inc., a primary care provider acquired by CVS Health, from August 2020 to May 2023. Ms. Klapstein holds a B.S. in Business Administration from Portland State University. - Julie Klapstein预计将在本次发行完成前加入我们的董事会。Klapstein女士是Availity，LLC的创始首席执行官，该公司是一家优化梦百合利益相关者之间关键业务和临床信息自动传递的健康信息网络。Klapstein女士从2001年到2011年担任Availity&8217；的首席执行官兼董事会成员。她于2017年2月至2017年6月担任私营公司America，Inc.医疗报销的临时首席执行官。Klapstein女士目前任职于Amedisys的董事会，在那里她任职于治理和质量委员会，在那里她担任薪酬委员会主席，以及NextGen梦百合的董事会，在那里她担任薪酬委员会主席。她目前也任职于两家私人公司的董事会。Klapstein之前从2012年1月到2014年9月担任Annie&8217；s Homedrown/Annies，Inc.两家上市公司董事，2011年4月到2014年11月担任Standard Register Inc.治理、薪酬和审计委员会成员。她也一直担任多个私人公司的董事。Klapstein女士在俄勒冈州波特兰的波特兰州立大学（Portland State University）获得学士学位。
- Julie Klapstein,has served as a member of board of directors since June 2024. Ms. Klapstein founded and served as the Chief Executive Officer of Availity, LLC, a healthcare information technology company, from May 2001 to March 2012. She also previously served as interim Chief Executive Officer of Medical Reimbursements of America, Inc., a provider of specialty reimbursement services, from February 2017 to June 2017. Ms. Klapstein has served on the boards of directors of Amedisys, Inc., a publicly held home healthcare provider, since April 2016, Claritev Corporation (f/k/a MultiPlan Corporation), a publicly held provider of business analytics and health cost management solutions, since November 2020, HealthCare Information Management, Inc., a robotic process automation company, since May 2024, Aptarro, Inc. (f/k/a Alpha II, LLC), a provider of revenue cycle management solutions for healthcare providers, since June 2024, and UnisLink Inc., a medical billing system vendor for healthcare providers, since July 2024, and also currently serves as an advisor to venture capital and private equity firms such as Andreessen Horowitz, GrowthCurve Capital, and Riverside Partners. She previously served on the boards of directors of numerous publicly held companies, including NextGen Healthcare, Inc., a healthcare technology company acquired by Thoma Bravo, from August 2017 to November 2023, and Oak Street Health, Inc., a primary care provider acquired by CVS Health, from August 2020 to May 2023. Ms. Klapstein holds a B.S. in Business Administration from Portland State University.
- Jonathan Root
-
Jonathan Root自2019年8月起担任EdgewiseTherapeutics，Inc.董事会成员。Root自1998年1月起担任多个U.S.Venture Partners’Funds管理成员。Root博士自2020年3月起担任SilverbackTherapeutics，Inc.董事会成员，自2011年9月起担任InariMedical，Inc.董事会成员，后者是一家专注于治疗大块血栓的医疗技术公司。此前，Root博士曾于2004年8月至2019年4月担任OncomedPharmaceuticals，Inc.（一家开发癌症疗法的上市制药公司）的董事会成员。此外，Root博士目前在梦百合行业的几家私营公司的董事会任职。Root博士在达特茅斯学院（Dartmouth College）获得经济学学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在佛罗里达大学医学院（University of Florida College of Medicine）获得医学博士学位。
Jonathan Root,served as a board member of Inari Medical, Inc., a medical technology company focusing on treatment of venous thromboembolism acquired by Stryker Corporation in February 2025, from September 2011 to February 2025, OncoMed Pharmaceuticals, Inc., a biopharmaceutical company developing cancer therapeutics, from August 2004 to April 2019, eFFECTOR Therapeutics, Inc., a pharmaceutical company developing cancer therapeutics, from April 2014 to February 2022, and Silverback Therapeutics, Inc., a biopharmaceutical company developing cancer treatment therapies acquired by ARS Pharmaceuticals in November 2022, from March 2020 to November 2022. Additionally, Dr. Root currently serves on the board of directors of several private companies in the healthcare industry. Dr. Root received an A.B. in economics from Dartmouth College, an M.D. from the University of Florida College of Medicine and an M.B.A. from Columbia Business School. - Jonathan Root自2019年8月起担任EdgewiseTherapeutics，Inc.董事会成员。Root自1998年1月起担任多个U.S.Venture Partners’Funds管理成员。Root博士自2020年3月起担任SilverbackTherapeutics，Inc.董事会成员，自2011年9月起担任InariMedical，Inc.董事会成员，后者是一家专注于治疗大块血栓的医疗技术公司。此前，Root博士曾于2004年8月至2019年4月担任OncomedPharmaceuticals，Inc.（一家开发癌症疗法的上市制药公司）的董事会成员。此外，Root博士目前在梦百合行业的几家私营公司的董事会任职。Root博士在达特茅斯学院（Dartmouth College）获得经济学学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在佛罗里达大学医学院（University of Florida College of Medicine）获得医学博士学位。
- Jonathan Root,served as a board member of Inari Medical, Inc., a medical technology company focusing on treatment of venous thromboembolism acquired by Stryker Corporation in February 2025, from September 2011 to February 2025, OncoMed Pharmaceuticals, Inc., a biopharmaceutical company developing cancer therapeutics, from August 2004 to April 2019, eFFECTOR Therapeutics, Inc., a pharmaceutical company developing cancer therapeutics, from April 2014 to February 2022, and Silverback Therapeutics, Inc., a biopharmaceutical company developing cancer treatment therapies acquired by ARS Pharmaceuticals in November 2022, from March 2020 to November 2022. Additionally, Dr. Root currently serves on the board of directors of several private companies in the healthcare industry. Dr. Root received an A.B. in economics from Dartmouth College, an M.D. from the University of Florida College of Medicine and an M.B.A. from Columbia Business School.
- Sachin Jain
-
Sachin Jain自2021年1月以来一直是我们的董事会成员。Jain博士目前是Scan Group and Health Plan（一家非营利性医疗保险优势计划）的总裁兼首席执行官。从2014年到2020年，他曾担任Caremore&Aspire Health公司（医疗保健交付系统）的多种领导职务，包括总裁兼首席执行官。从2012年到2014年，Jain博士担任默克公司的首席医疗和信息官。从2009年到2011年，他曾担任美国卫生和人类服务部的多种领导职务，包括担任医疗保险和医疗补助服务中心的高级顾问。贾恩博士是斯坦福大学医学院的兼职医学教授，也是《福布斯》杂志的撰稿人。他是美国健康保险计划AHIP、Abode Hospice和Make-a-Wish Foundation的董事会成员。他也是Aspen Institute Health Innovator’；的研究员。
Sachin Jain,has served as a member of board of directors since June 2024. Dr. Jain has served as President, Chief Executive Officer, and a member of the board of directors of SCAN Group and SCAN Health Plan, a not-for-profit Medicare Advantage plan, since July 2020, and as an Academic Hospitalist at the U.S. Department of Veterans Affairs since April 2021. He has also served as an Adjunct Professor of Medicine at Stanford University School of Medicine since August 2015. From December 2014 to May 2020, Dr. Jain served in increasingly senior leadership roles at Carelon Health (f/k/a CareMore Health) and Aspire Health, healthcare delivery systems owned by Elevance Health, Inc. (f/k/a Anthem, Inc.), a publicly held health insurance provider, including most recently serving as President and Chief Executive Officer. Prior to that, Dr. Jain served as Chief Medical Information and Innovation Officer at Merck & Co., a publicly held pharmaceutical company, from October 2011 to December 2014. Dr. Jain has served as a member of the boards of directors of America's Health Insurance Plans (AHIP), a political advocacy and trade association of health insurance companies, since November 2020, and Advantage Healthcare Services, a specialty pharmacy company, since February 2024. He previously served on the boards of directors of the national Make-A-Wish Foundation, from July 2018 to February 2023, Adobe Healthcare, a home healthcare company, from July 2020 to April 2021, Cardiovascular Systems Inc., a medical device company acquired by Abbott, from January 2021 to November 2022, Biofourmis Inc., a biotechnology company, from July 2022 to December 2023, and Cue Health Inc., a then publicly held diagnostic testing company, from October 2022 to May 2024. Dr. Jain holds an A.B. in Government from Harvard University, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School. - Sachin Jain自2021年1月以来一直是我们的董事会成员。Jain博士目前是Scan Group and Health Plan（一家非营利性医疗保险优势计划）的总裁兼首席执行官。从2014年到2020年，他曾担任Caremore&Aspire Health公司（医疗保健交付系统）的多种领导职务，包括总裁兼首席执行官。从2012年到2014年，Jain博士担任默克公司的首席医疗和信息官。从2009年到2011年，他曾担任美国卫生和人类服务部的多种领导职务，包括担任医疗保险和医疗补助服务中心的高级顾问。贾恩博士是斯坦福大学医学院的兼职医学教授，也是《福布斯》杂志的撰稿人。他是美国健康保险计划AHIP、Abode Hospice和Make-a-Wish Foundation的董事会成员。他也是Aspen Institute Health Innovator’；的研究员。
- Sachin Jain,has served as a member of board of directors since June 2024. Dr. Jain has served as President, Chief Executive Officer, and a member of the board of directors of SCAN Group and SCAN Health Plan, a not-for-profit Medicare Advantage plan, since July 2020, and as an Academic Hospitalist at the U.S. Department of Veterans Affairs since April 2021. He has also served as an Adjunct Professor of Medicine at Stanford University School of Medicine since August 2015. From December 2014 to May 2020, Dr. Jain served in increasingly senior leadership roles at Carelon Health (f/k/a CareMore Health) and Aspire Health, healthcare delivery systems owned by Elevance Health, Inc. (f/k/a Anthem, Inc.), a publicly held health insurance provider, including most recently serving as President and Chief Executive Officer. Prior to that, Dr. Jain served as Chief Medical Information and Innovation Officer at Merck & Co., a publicly held pharmaceutical company, from October 2011 to December 2014. Dr. Jain has served as a member of the boards of directors of America's Health Insurance Plans (AHIP), a political advocacy and trade association of health insurance companies, since November 2020, and Advantage Healthcare Services, a specialty pharmacy company, since February 2024. He previously served on the boards of directors of the national Make-A-Wish Foundation, from July 2018 to February 2023, Adobe Healthcare, a home healthcare company, from July 2020 to April 2021, Cardiovascular Systems Inc., a medical device company acquired by Abbott, from January 2021 to November 2022, Biofourmis Inc., a biotechnology company, from July 2022 to December 2023, and Cue Health Inc., a then publicly held diagnostic testing company, from October 2022 to May 2024. Dr. Jain holds an A.B. in Government from Harvard University, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School.
- Anne Beal
-
Anne Beal，作为一名医生和企业家，结合对患者倡导的热情，为董事会带来了丰富的医疗保健经验。她是公认的健康政策专家，参与制定全球和国家计划，以改善所有患者群体获得医疗保健的机会，并确保患者的声音在研究计划中得到反映。在担任现任职务之前，安妮曾在哈佛医学院和麻省总医院工作了六年，在那里她担任儿科讲师。她还曾在英联邦基金和安泰基金会担任领导职务。Anne此前曾担任美国以患者为中心的结果研究所副执行董事兼首席参与官，以及赛诺菲首席患者官兼患者解决方案全球负责人。此外，安妮此前是Academy Health的董事会成员。
Anne Beal,has served as a member of board of directors since September 2024. Dr. Beal has served as the founder and Chief Executive Officer of AbsoluteJOI Skincare, a clean beauty company, since May 2019. Prior to that, she served as Chief Patient Officer and Senior Vice President, Global Head of Patient Solutions at Sanofi S.A., a publicly held pharmaceutical company, from April 2014 to April 2019, and as Deputy Executive Director and Chief Officer for Engagement at the Patient-Centered Outcomes Research Institute, a funder of patient-centered comparative clinical effectiveness research in the U.S., from November 2011 to March 2014. Dr. Beal has served on the boards of directors of GSK plc, a publicly held pharmaceutical company, since April 2021, and Prolacta Bioscience, a privately held life sciences company, since November 2021, and on the board of trustees of Brown University since July 2024. Dr. Beal previously served on the board of directors of AcademyHealth, a non-profit health research and policy organization, for two four-year terms from 2007 to 2011 and 2018 to 2022, including as board chair from 2019 to 2020. Dr. Beal holds an A.B. in Biology from Brown University, an M.P.H. from Columbia University's Mailman School of Public Health, and an M.D. from Weill Medical College of Cornell University. - Anne Beal，作为一名医生和企业家，结合对患者倡导的热情，为董事会带来了丰富的医疗保健经验。她是公认的健康政策专家，参与制定全球和国家计划，以改善所有患者群体获得医疗保健的机会，并确保患者的声音在研究计划中得到反映。在担任现任职务之前，安妮曾在哈佛医学院和麻省总医院工作了六年，在那里她担任儿科讲师。她还曾在英联邦基金和安泰基金会担任领导职务。Anne此前曾担任美国以患者为中心的结果研究所副执行董事兼首席参与官，以及赛诺菲首席患者官兼患者解决方案全球负责人。此外，安妮此前是Academy Health的董事会成员。
- Anne Beal,has served as a member of board of directors since September 2024. Dr. Beal has served as the founder and Chief Executive Officer of AbsoluteJOI Skincare, a clean beauty company, since May 2019. Prior to that, she served as Chief Patient Officer and Senior Vice President, Global Head of Patient Solutions at Sanofi S.A., a publicly held pharmaceutical company, from April 2014 to April 2019, and as Deputy Executive Director and Chief Officer for Engagement at the Patient-Centered Outcomes Research Institute, a funder of patient-centered comparative clinical effectiveness research in the U.S., from November 2011 to March 2014. Dr. Beal has served on the boards of directors of GSK plc, a publicly held pharmaceutical company, since April 2021, and Prolacta Bioscience, a privately held life sciences company, since November 2021, and on the board of trustees of Brown University since July 2024. Dr. Beal previously served on the board of directors of AcademyHealth, a non-profit health research and policy organization, for two four-year terms from 2007 to 2011 and 2018 to 2022, including as board chair from 2019 to 2020. Dr. Beal holds an A.B. in Biology from Brown University, an M.P.H. from Columbia University's Mailman School of Public Health, and an M.D. from Weill Medical College of Cornell University.
- Sean Duffy
-
肖恩·达菲，自2011年4月起担任联合创始人、首席执行官，并担任Omada Health，Inc.董事会成员。从2010年6月到2011年4月，Duffy先生在IDEO的健康和保健实践中任职于设计公司IDEO LP。他还曾于2007年6月至2009年8月在全球科技公司Google LLC的人员分析小组工作。Duffy先生拥有哥伦比亚大学神经科学学士学位，并于2009年7月至2010年5月在哈佛大学的联合医学博士和医学硕士项目中注册。
Sean Duffy,has served as co-founder, Chief Executive Officer, and as a member of Omada Health, Inc. board of directors since April 2011. From June 2010 to April 2011, Mr. Duffy worked at IDEO LP, a design firm, in IDEO's health and wellness practice. He also previously worked in the people analytics group at Google LLC, a global technology company, from June 2007 to August 2009. Mr. Duffy holds a B.A. in Neuroscience from Columbia University and was enrolled in the combined M.D. and M.B.A. program at Harvard University from July 2009 to May 2010. - 肖恩·达菲，自2011年4月起担任联合创始人、首席执行官，并担任Omada Health，Inc.董事会成员。从2010年6月到2011年4月，Duffy先生在IDEO的健康和保健实践中任职于设计公司IDEO LP。他还曾于2007年6月至2009年8月在全球科技公司Google LLC的人员分析小组工作。Duffy先生拥有哥伦比亚大学神经科学学士学位，并于2009年7月至2010年5月在哈佛大学的联合医学博士和医学硕士项目中注册。
- Sean Duffy,has served as co-founder, Chief Executive Officer, and as a member of Omada Health, Inc. board of directors since April 2011. From June 2010 to April 2011, Mr. Duffy worked at IDEO LP, a design firm, in IDEO's health and wellness practice. He also previously worked in the people analytics group at Google LLC, a global technology company, from June 2007 to August 2009. Mr. Duffy holds a B.A. in Neuroscience from Columbia University and was enrolled in the combined M.D. and M.B.A. program at Harvard University from July 2009 to May 2010.
- Adam Stavisky
-
Adam Stavisky，自2024年6月起担任Omada Health，Inc.董事会成员。Stavisky先生于2018年2月至2024年3月期间在全球上市零售商沃尔玛公司担任美国福利高级副总裁。在此之前，斯塔维斯基先生于2004年11月至2018年2月期间在金融服务公司富达投资担任越来越高级的领导职务，最近担任工作场所咨询高级副总裁。斯塔维斯基此前曾于2019年4月至2024年2月担任ERISA行业委员会的董事会成员，该委员会是一个全国性倡导组织，代表向其雇员提供健康保险和其他福利的大型雇主，并于2019年10月至2024年2月担任健康政策组织Business Group on Health的董事会成员。Stavisky先生拥有西北大学数学学士学位和加州大学洛杉矶分校数学硕士学位。
Adam Stavisky,has served as a member of board of directors since June 2024. Mr. Stavisky served as Senior Vice President, U.S. Benefits at Walmart Inc., a publicly held global retailer, from February 2018 to March 2024. Prior to that, Mr. Stavisky held increasingly senior leadership positions at Fidelity Investments, a financial services company, from November 2004 to February 2018, most recently serving as Senior Vice President, Workplace Consulting. Mr. Stavisky previously served on the boards of directors of the ERISA Industry Committee, a national advocacy organization that represents large employers who provide health insurance and other benefits to their employees, from April 2019 to February 2024, and the Business Group on Health, a health policy organization, from October 2019 to February 2024. Mr. Stavisky holds a B.A. in Mathematics from Northwestern University and an M.A. in Mathematics from the University of California, Los Angeles. - Adam Stavisky，自2024年6月起担任Omada Health，Inc.董事会成员。Stavisky先生于2018年2月至2024年3月期间在全球上市零售商沃尔玛公司担任美国福利高级副总裁。在此之前，斯塔维斯基先生于2004年11月至2018年2月期间在金融服务公司富达投资担任越来越高级的领导职务，最近担任工作场所咨询高级副总裁。斯塔维斯基此前曾于2019年4月至2024年2月担任ERISA行业委员会的董事会成员，该委员会是一个全国性倡导组织，代表向其雇员提供健康保险和其他福利的大型雇主，并于2019年10月至2024年2月担任健康政策组织Business Group on Health的董事会成员。Stavisky先生拥有西北大学数学学士学位和加州大学洛杉矶分校数学硕士学位。
- Adam Stavisky,has served as a member of board of directors since June 2024. Mr. Stavisky served as Senior Vice President, U.S. Benefits at Walmart Inc., a publicly held global retailer, from February 2018 to March 2024. Prior to that, Mr. Stavisky held increasingly senior leadership positions at Fidelity Investments, a financial services company, from November 2004 to February 2018, most recently serving as Senior Vice President, Workplace Consulting. Mr. Stavisky previously served on the boards of directors of the ERISA Industry Committee, a national advocacy organization that represents large employers who provide health insurance and other benefits to their employees, from April 2019 to February 2024, and the Business Group on Health, a health policy organization, from October 2019 to February 2024. Mr. Stavisky holds a B.A. in Mathematics from Northwestern University and an M.A. in Mathematics from the University of California, Los Angeles.
- Anne Beal
-
Anne Beal是公认的卫生政策专家，参与制定全球和国家计划，以改善所有患者群体获得医疗保健的机会，并确保患者的声音在研究计划中得到反映。在担任现任职务之前，Anne曾在哈佛医学院和马萨诸塞州总医院工作了六年，在那里她担任儿科讲师。她还曾在Commonalth Fund和Aetna基金会担任领导职务。Anne曾担任previoly副执行董事兼以患者为中心的结果研究所首席参与官，以及赛诺菲首席患者官兼患者解决方案全球负责人。此外，安妮还曾是Academy Health的董事会成员。
Anne Beal is a recognised health policy expert in the development of global and national programmes for improving healthcare access for all patient groups and in ensuring the voice of patients is reflected in research programmes.Prior to her current roles, Anne spent six years at Harvard Medical School and Massachetts General Hospital, where she was an instructor in paediatrics. She has also held leadership roles at the Commonalth Fund and the Aetna Foundation. Anne was previoly Deputy Executive Director and Chief Engagement Officer for The Patient Centered Outcomes Research Institute in the and Chief Patient Officer and Global Head of Patient Solutions at Sanofi. In addition, Anne was previoly a member of the Board of Academy Health. - Anne Beal是公认的卫生政策专家，参与制定全球和国家计划，以改善所有患者群体获得医疗保健的机会，并确保患者的声音在研究计划中得到反映。在担任现任职务之前，Anne曾在哈佛医学院和马萨诸塞州总医院工作了六年，在那里她担任儿科讲师。她还曾在Commonalth Fund和Aetna基金会担任领导职务。Anne曾担任previoly副执行董事兼以患者为中心的结果研究所首席参与官，以及赛诺菲首席患者官兼患者解决方案全球负责人。此外，安妮还曾是Academy Health的董事会成员。
- Anne Beal is a recognised health policy expert in the development of global and national programmes for improving healthcare access for all patient groups and in ensuring the voice of patients is reflected in research programmes.Prior to her current roles, Anne spent six years at Harvard Medical School and Massachetts General Hospital, where she was an instructor in paediatrics. She has also held leadership roles at the Commonalth Fund and the Aetna Foundation. Anne was previoly Deputy Executive Director and Chief Engagement Officer for The Patient Centered Outcomes Research Institute in the and Chief Patient Officer and Global Head of Patient Solutions at Sanofi. In addition, Anne was previoly a member of the Board of Academy Health.
- Jeryl Hilleman
-
Jeryl Hilleman从2008年1月开始担任Minerva Neurosciences, Inc.首席财务官。加入阿米瑞斯公司（Amyris）以前，从1997年到2007年6月，她担任赛美科技有限公司（Symyx Technologies, Inc.）的执行副总裁和首席财务官，这是一家研发基础设施公司，其为技术公司提供科学软件与研究服务。加入赛美科技以前，Hilleman女士在两家生物技术公司任职，从1992年到1997年，在美国杰龙生物医药公司（Geron Corporation）担任财务部副总裁，这是一家生物医药公司，从1987年到1992年，担任Cytel Corporation的首席财务官，这是一家生物医药公司。 Hilleman女士在布朗大学（M Brown University）获得历史学文学学士学位，并在沃顿商学院（Wharton Graduate School of Business）获得工商管理硕士学位。
Jeryl Hilleman,has served as a member of board of directors since April 2019, including as Chairperson since July 2020. Ms. Hilleman previously served as Chief Financial Officer of several publicly held healthcare companies, including most recently at Intersect ENT, Inc., a medical device company subsequently acquired by Medtronic plc, from June 2014 to December 2019. Prior to joining Intersect ENT, Ms. Hilleman was Chief Financial Officer of publicly held Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals, Inc., Amyris, Inc., a renewable products company, and Symyx Technologies, Inc., a software and instruments company acquired by Accelrys, Inc. She has served on the boards of directors of NovoCure Limited, a publicly held oncology company, since July 2018, SI-Bone, Inc., a publicly held medical device company, since December 2019, and HilleVax, Inc., a publicly held biopharmaceutical company, since April 2021. In addition, she previously served on the boards of directors of Xenoport Inc., a publicly held biotechnology company, from January 2005 to July 2016, Talis Biomedical Corporation, a publicly held diagnostics company, from April 2021 to June 2022, Minerva Neurosciences, Inc., a publicly held biotechnology company, from July 2018 to August 2024, and Cutera, Inc., a publicly held medical device company, from July 2024 to February 2025. Ms. Hilleman holds an A.B. in History from Brown University and an M.B.A. from The Wharton School at the University of Pennsylvania. - Jeryl Hilleman从2008年1月开始担任Minerva Neurosciences, Inc.首席财务官。加入阿米瑞斯公司（Amyris）以前，从1997年到2007年6月，她担任赛美科技有限公司（Symyx Technologies, Inc.）的执行副总裁和首席财务官，这是一家研发基础设施公司，其为技术公司提供科学软件与研究服务。加入赛美科技以前，Hilleman女士在两家生物技术公司任职，从1992年到1997年，在美国杰龙生物医药公司（Geron Corporation）担任财务部副总裁，这是一家生物医药公司，从1987年到1992年，担任Cytel Corporation的首席财务官，这是一家生物医药公司。 Hilleman女士在布朗大学（M Brown University）获得历史学文学学士学位，并在沃顿商学院（Wharton Graduate School of Business）获得工商管理硕士学位。
- Jeryl Hilleman,has served as a member of board of directors since April 2019, including as Chairperson since July 2020. Ms. Hilleman previously served as Chief Financial Officer of several publicly held healthcare companies, including most recently at Intersect ENT, Inc., a medical device company subsequently acquired by Medtronic plc, from June 2014 to December 2019. Prior to joining Intersect ENT, Ms. Hilleman was Chief Financial Officer of publicly held Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals, Inc., Amyris, Inc., a renewable products company, and Symyx Technologies, Inc., a software and instruments company acquired by Accelrys, Inc. She has served on the boards of directors of NovoCure Limited, a publicly held oncology company, since July 2018, SI-Bone, Inc., a publicly held medical device company, since December 2019, and HilleVax, Inc., a publicly held biopharmaceutical company, since April 2021. In addition, she previously served on the boards of directors of Xenoport Inc., a publicly held biotechnology company, from January 2005 to July 2016, Talis Biomedical Corporation, a publicly held diagnostics company, from April 2021 to June 2022, Minerva Neurosciences, Inc., a publicly held biotechnology company, from July 2018 to August 2024, and Cutera, Inc., a publicly held medical device company, from July 2024 to February 2025. Ms. Hilleman holds an A.B. in History from Brown University and an M.B.A. from The Wharton School at the University of Pennsylvania.
- Trevor Fetter
-
Trevor Fetter在2002年11月获委任为Tenet公司总裁，2003年9月担任公司首席执行官，从2000年3月至2002年11月他是Broadlane公司董事长兼首席执行官。从1995年10月到2000年2月，他担任过多个高级管理职位，包括财务总监。他的职业生涯始于美林资本市场，在那里，他专注于企业融资及顾问服务，为娱乐和医疗保健行业服务。1988年，他加入了Metro-Goldwyn-Mayer公司，在那里他承担广泛的企业和经营责任，后来上升到执行副总裁兼首席财务官职位。他持有斯坦福大学的经济学学士学位和哈佛商学院的工商管理硕士学位。他是另外一个上市公司--哈特福德金融服务集团公司的董事会成员。
Trevor Fetter,has served as a member of board of directors since March 2021. Mr. Fetter has served as a Senior Lecturer at Harvard University since January 2019 and previously served in numerous executive leadership roles at Tenet Healthcare, a publicly held healthcare services company, including as Chief Executive Officer from September 2003 to October 2017, President from November 2002 to October 2017, Chairman from May 2015 to October 2017, and Executive Vice President and Chief Financial Officer from October 1995 to February 2000. Mr. Fetter has served on the board of directors of The Hartford Financial Services Group, Inc., a publicly held investment and insurance company, since January 2007, including as Lead Director since May 2017, and he also currently serves on the board of directors of a privately held healthcare services company. Mr. Fetter holds an A.B. in Economics from Stanford University and an M.B.A. from Harvard Business School. - Trevor Fetter在2002年11月获委任为Tenet公司总裁，2003年9月担任公司首席执行官，从2000年3月至2002年11月他是Broadlane公司董事长兼首席执行官。从1995年10月到2000年2月，他担任过多个高级管理职位，包括财务总监。他的职业生涯始于美林资本市场，在那里，他专注于企业融资及顾问服务，为娱乐和医疗保健行业服务。1988年，他加入了Metro-Goldwyn-Mayer公司，在那里他承担广泛的企业和经营责任，后来上升到执行副总裁兼首席财务官职位。他持有斯坦福大学的经济学学士学位和哈佛商学院的工商管理硕士学位。他是另外一个上市公司--哈特福德金融服务集团公司的董事会成员。
- Trevor Fetter,has served as a member of board of directors since March 2021. Mr. Fetter has served as a Senior Lecturer at Harvard University since January 2019 and previously served in numerous executive leadership roles at Tenet Healthcare, a publicly held healthcare services company, including as Chief Executive Officer from September 2003 to October 2017, President from November 2002 to October 2017, Chairman from May 2015 to October 2017, and Executive Vice President and Chief Financial Officer from October 1995 to February 2000. Mr. Fetter has served on the board of directors of The Hartford Financial Services Group, Inc., a publicly held investment and insurance company, since January 2007, including as Lead Director since May 2017, and he also currently serves on the board of directors of a privately held healthcare services company. Mr. Fetter holds an A.B. in Economics from Stanford University and an M.B.A. from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Sean Duffy
肖恩·达菲，自2011年4月起担任联合创始人、首席执行官，并担任Omada Health，Inc.董事会成员。从2010年6月到2011年4月，Duffy先生在IDEO的健康和保健实践中任职于设计公司IDEO LP。他还曾于2007年6月至2009年8月在全球科技公司Google LLC的人员分析小组工作。Duffy先生拥有哥伦比亚大学神经科学学士学位，并于2009年7月至2010年5月在哈佛大学的联合医学博士和医学硕士项目中注册。
Sean Duffy,has served as co-founder, Chief Executive Officer, and as a member of Omada Health, Inc. board of directors since April 2011. From June 2010 to April 2011, Mr. Duffy worked at IDEO LP, a design firm, in IDEO's health and wellness practice. He also previously worked in the people analytics group at Google LLC, a global technology company, from June 2007 to August 2009. Mr. Duffy holds a B.A. in Neuroscience from Columbia University and was enrolled in the combined M.D. and M.B.A. program at Harvard University from July 2009 to May 2010.- 肖恩·达菲，自2011年4月起担任联合创始人、首席执行官，并担任Omada Health，Inc.董事会成员。从2010年6月到2011年4月，Duffy先生在IDEO的健康和保健实践中任职于设计公司IDEO LP。他还曾于2007年6月至2009年8月在全球科技公司Google LLC的人员分析小组工作。Duffy先生拥有哥伦比亚大学神经科学学士学位，并于2009年7月至2010年5月在哈佛大学的联合医学博士和医学硕士项目中注册。
- Sean Duffy,has served as co-founder, Chief Executive Officer, and as a member of Omada Health, Inc. board of directors since April 2011. From June 2010 to April 2011, Mr. Duffy worked at IDEO LP, a design firm, in IDEO's health and wellness practice. He also previously worked in the people analytics group at Google LLC, a global technology company, from June 2007 to August 2009. Mr. Duffy holds a B.A. in Neuroscience from Columbia University and was enrolled in the combined M.D. and M.B.A. program at Harvard University from July 2009 to May 2010.
- Steve Cook
Steve Cook，自2021年7月起担任Omada Health，Inc. 首席财务官。在加入Omada Health，Inc之前，Cook先生曾在1Life Healthcare，Inc.（d/b/a One Medical）担任多个财务职务，该公司是一家现由亚马逊拥有的初级保健提供商，曾于2021年1月至2021年7月担任副总裁兼战略财务主管，于2020年1月至2020年12月担任战略财务高级总监兼FP & A主管，并于2018年2月至2019年12月担任战略财务总监。在此之前，他于2011年10月至2018年1月在基于云的软件公司赛富时公司担任过各种财务职务。库克先生拥有加州大学圣地亚哥分校政治学学士学位。
Steve Cook,has served as Chief Financial Officer since July 2021. Prior to joining company, Mr. Cook held various finance roles at 1Life Healthcare, Inc., d/b/a One Medical, a primary care provider now owned by Amazon, serving as Vice President, Head of Strategic Finance from January 2021 to July 2021, Senior Director, Strategic Finance and Head of FP&A from January 2020 to December 2020, and Director, Strategic Finance from February 2018 to December 2019. Prior to that, he held various finance roles at Salesforce, Inc., a cloud-based software company, from October 2011 to January 2018. Mr. Cook holds a B.A. in Political Science from the University of California, San Diego.- Steve Cook，自2021年7月起担任Omada Health，Inc. 首席财务官。在加入Omada Health，Inc之前，Cook先生曾在1Life Healthcare，Inc.（d/b/a One Medical）担任多个财务职务，该公司是一家现由亚马逊拥有的初级保健提供商，曾于2021年1月至2021年7月担任副总裁兼战略财务主管，于2020年1月至2020年12月担任战略财务高级总监兼FP & A主管，并于2018年2月至2019年12月担任战略财务总监。在此之前，他于2011年10月至2018年1月在基于云的软件公司赛富时公司担任过各种财务职务。库克先生拥有加州大学圣地亚哥分校政治学学士学位。
- Steve Cook,has served as Chief Financial Officer since July 2021. Prior to joining company, Mr. Cook held various finance roles at 1Life Healthcare, Inc., d/b/a One Medical, a primary care provider now owned by Amazon, serving as Vice President, Head of Strategic Finance from January 2021 to July 2021, Senior Director, Strategic Finance and Head of FP&A from January 2020 to December 2020, and Director, Strategic Finance from February 2018 to December 2019. Prior to that, he held various finance roles at Salesforce, Inc., a cloud-based software company, from October 2011 to January 2018. Mr. Cook holds a B.A. in Political Science from the University of California, San Diego.
- Wei Li Shao
李威邵，自2021年12月起担任总裁，此前曾于2019年5月至2021年12月担任首席商务官。在加入公司之前，邵先生曾于2001年至2019年2月在全球制药公司礼来公司担任多个职务，包括礼来中国糖尿病副总裁、礼来台湾公司新西兰总经理，最近担任美国神经科学业务部副总裁。邵先生拥有威斯康星大学麦迪逊分校的生物化学学士学位和印第安纳大学凯利商学院的工商管理硕士学位。
Wei Li Shao,has served as President since December 2021, after previously serving as Chief Commercial Officer from May 2019 to December 2021. Prior to joining company, Mr. Shao held various roles at Eli Lilly and Company, a global pharmaceutical company, from 2001 to February 2019, including Vice President of Lilly China Diabetes, General Manager of Lilly Taiwan, Lilly New Zealand, and most recently as Vice President of the U.S. Neuroscience Business Unit. Mr. Shao holds a B.S. in Biochemistry from the University of Wisconsin-Madison and an M.B.A. from Indiana University's Kelley School of Business.- 李威邵，自2021年12月起担任总裁，此前曾于2019年5月至2021年12月担任首席商务官。在加入公司之前，邵先生曾于2001年至2019年2月在全球制药公司礼来公司担任多个职务，包括礼来中国糖尿病副总裁、礼来台湾公司新西兰总经理，最近担任美国神经科学业务部副总裁。邵先生拥有威斯康星大学麦迪逊分校的生物化学学士学位和印第安纳大学凯利商学院的工商管理硕士学位。
- Wei Li Shao,has served as President since December 2021, after previously serving as Chief Commercial Officer from May 2019 to December 2021. Prior to joining company, Mr. Shao held various roles at Eli Lilly and Company, a global pharmaceutical company, from 2001 to February 2019, including Vice President of Lilly China Diabetes, General Manager of Lilly Taiwan, Lilly New Zealand, and most recently as Vice President of the U.S. Neuroscience Business Unit. Mr. Shao holds a B.S. in Biochemistry from the University of Wisconsin-Madison and an M.B.A. from Indiana University's Kelley School of Business.